TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

TAVR still a safe treatment option for immunocompromised patients
While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.
Edwards Lifesciences shares positive outlook for 2026, pointing to continued importance of TAVR
The company expects TAVR sales alone to be as high as $4.9 billion in 2026. Other minimally invasive therapies are projected to make a major impact as well.
3-in-1 TAVR guidewire linked to faster procedures, less radiation
The sensor-guided device delivers continuous hemodynamic measurements and rapid left ventricular pacing during TAVR procedures. Back in 2023, it was at the heart of a $253 million acquisition.
AI has already transformed TAVR care—and the best is yet to come
Advanced AI technologies are starting to play a bigger role in TAVR care, helping cardiologists plan ahead, make critical decisions and predict potential complications. Looking to the future, though, it is clear this is just the beginning.
Waiting is no longer ‘good medicine’: Data shows treating severe AS with TAVR before symptoms appear improves outcomes, reduces costs
TAVR is increasingly seen as the preferred option for symptomatic severe aortic stenosis, and clinical guidelines in the U.S. reserve their highest recommendations for patients who experience symptoms. Asymptomatic patients, meanwhile, are typically managed by clinical surveillance or a “watch and wait” approach; no symptoms means no treatment.

TAVR still a safe treatment option for immunocompromised patients

While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.

Edwards Lifesciences shares positive outlook for 2026, pointing to continued importance of TAVR

The company expects TAVR sales alone to be as high as $4.9 billion in 2026. Other minimally invasive therapies are projected to make a major impact as well.

SavvyWire OpSens TAVR guidewire owned by Haemonetics

3-in-1 TAVR guidewire linked to faster procedures, less radiation

The sensor-guided device delivers continuous hemodynamic measurements and rapid left ventricular pacing during TAVR procedures. Back in 2023, it was at the heart of a $253 million acquisition.

Cardiologist Heart Doctor Tablet Technology

AI has already transformed TAVR care—and the best is yet to come

Advanced AI technologies are starting to play a bigger role in TAVR care, helping cardiologists plan ahead, make critical decisions and predict potential complications. Looking to the future, though, it is clear this is just the beginning.

cardiologist patient heart compensation starting salary 2022 interventional cardiologist

Waiting is no longer ‘good medicine’: Data shows treating severe AS with TAVR before symptoms appear improves outcomes, reduces costs

Sponsored by Edwards Lifesciences

TAVR is increasingly seen as the preferred option for symptomatic severe aortic stenosis, and clinical guidelines in the U.S. reserve their highest recommendations for patients who experience symptoms. Asymptomatic patients, meanwhile, are typically managed by clinical surveillance or a “watch and wait” approach; no symptoms means no treatment.

Medicare data reveal ‘highly concerning’ TAVR trends—are hospital rankings to blame?

Hospitals could be turning away high-risk heart patients to help their TAVR programs receive a higher ranking, according to new research published in JACC: Cardiovascular Interventions.

FDA clears TAVR guidewire built with BASILICA in mind

The Telltale system was designed to assist cardiologists when BASILICA is required prior to TAVR.

‘Strongest growth in over a decade’: Heart tech helps Medtronic beat earnings expectations

The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward.